Ensysce Biosciences, Inc.
ENSCAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2023 |
| Lake Street | maintain | Buy | Nov 17, 2022 |
| Lake Street | maintain | Buy | Nov 30, 2021 |
Earnings History
Next report: Nov 13, 2026 · EPS est. $-0.12| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.20 | $-0.20 | $1.2M | $1.2M |
| May 15, 2026 | $-0.52 | $-0.73 | $1.0M | $1.9M |
| Mar 30, 2026 | $-0.75 | $-1.26 | $1.9M | $503.0K |
| Nov 14, 2025 | $-1.29 | $-0.85 | $493.1K | $700.0K |
| Aug 13, 2025 | $-0.79 | $-1.02 | — | $650.0K |
| May 13, 2025 | $-1.39 | $-3.02 | $1.3M | $650.0K |
| Mar 19, 2025 | $-2.90 | $-2.74 | $1.3M | $245.0K |
| Nov 12, 2024 | $1.05 | $-0.29 | $3.4M | $3.4M |
News
~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~ SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing innovative neuroplastogenic therapies beyond mood disorders, with an initial focus on Complex Regional Pain Syndrome ("CRPS") today announced that James Morrison, President of Ensysce Biosciences, participated in t…
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and Hypermarcas (OTCMKTS:HYPMY - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability. Risk and Volatility Ensysce Biosciences has a beta of
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced the submission of the protocol for a Phase 2a clinical study of CY200, the Company…
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), hosted a symposium at PainWeek 2026. The Symposium was attended by more than 320 pain management professionals.
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced that Richard Langford, Chief Medical Officer of Cy Biopharma, has been selected to present in person at the U.S. Food and Drug Administration's ("FDA") public hearing, "Considerations for Po…
SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events. 2026 Cantor Global Healthcare Conference being held Wednesday, September 9th to Saturday, September 12th…
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, and advancing next-generation pain and central nervous system therapeutics designed to reduce abuse and ove…
~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~ ~Discussions to feature a first-in-class approach to neural reset and novel chemical safety switch technology ~ SAN DIEGO, CA / ACCESS Newswire / August 20, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain, today an…
Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome Up to $77 million in new funding with the acquisition of Cy Biopharma Company to host a Corporate Update Call on Tuesday, August 18, 2026, at 11:00 a.m. ET SAN DIEGO, CA / ACCESS Newswire / August 13, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on comp…
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and CannAmerica Brands (OTCMKTS:CNNXF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Valuation and Earnings This table compares Ensysce Biosciences